Contrasting of Seattle Genetics Inc. (SGEN) and Nektar Therapeutics (NASDAQ:NKTR)

Since Seattle Genetics Inc. (NASDAQ:SGEN) and Nektar Therapeutics (NASDAQ:NKTR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seattle Genetics Inc. 654.70M 16.32 222.69M -1.10 0.00
Nektar Therapeutics 1.25B 6.42 745.70M 3.96 9.25

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Seattle Genetics Inc. and Nektar Therapeutics.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Seattle Genetics Inc. -34.01% -13.8% -11.8%
Nektar Therapeutics 59.66% 78.6% 53.6%

Risk & Volatility

A beta of 2.19 shows that Seattle Genetics Inc. is 119.00% more volatile than Standard and Poor’s 500. Competitively, Nektar Therapeutics’s beta is 2.87 which is 187.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Seattle Genetics Inc. are 3.7 and 3.3. Competitively, Nektar Therapeutics has 13.9 and 13.8 for Current and Quick Ratio. Nektar Therapeutics’s better ability to pay short and long-term obligations than Seattle Genetics Inc.

Analyst Ratings

The Recommendations and Ratings for Seattle Genetics Inc. and Nektar Therapeutics are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seattle Genetics Inc. 0 1 2 2.67
Nektar Therapeutics 0 0 3 3.00

$85.67 is Seattle Genetics Inc.’s consensus price target while its potential upside is 28.77%. On the other hand, Nektar Therapeutics’s potential upside is 58.94% and its consensus price target is $73.67. The results provided earlier shows that Nektar Therapeutics appears more favorable than Seattle Genetics Inc., based on analyst opinion.

Institutional and Insider Ownership

Seattle Genetics Inc. and Nektar Therapeutics has shares held by institutional investors as follows: 0% and 94.2%. Insiders held roughly 0.9% of Seattle Genetics Inc.’s shares. Insiders Competitively, held 0.9% of Nektar Therapeutics shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seattle Genetics Inc. -3.08% -0.49% -22.02% -9.12% 5.9% 13.36%
Nektar Therapeutics -9.23% -3.4% -44.94% -30.86% -33.14% -38.61%

For the past year Seattle Genetics Inc. has 13.36% stronger performance while Nektar Therapeutics has -38.61% weaker performance.

Summary

On 11 of the 13 factors Nektar Therapeutics beats Seattle Genetics Inc.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The companyÂ’s drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214; and a strategic collaboration with Eli Lilly and Company to develop and commercialize NKTR-358. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.